Darifenacin, Solifenacin Urinary Incontinence Drugs Could Hit Market In 2003
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
The urinary incontinence market could see the entry of two significant competitors in 2003, with recent NDA submissions for Pfizer’s darifenacin and Yamanouchi’s solifenacin (YM-905).
You may also be interested in...
Indevus Sanctura Comparative Claims Not Supported By NDA, FDA Finds
Indevus’ NDA for Sanctura did not support a claim that trospium has a superior central nervous system adverse event profile to other anticholinergics, FDA review documents indicate.
NME "Approvables" Outnumber Approvals Six To Two In October
An "approvable" action was three times more likely than approval for the new molecular entities with user fee goals in October, according to an analysis by Pharmaceutical Approvals Monthly.
Market Analysis From Decision Resources
Urinary Incontinence